义翘神州 (301047)

Sino Biological Inc.

ASZ

Tags

AI HealthcareContract Research Organization (CXO)Artificial Intelligence (AI)ImmunotherapySynthetic BiologySmart HealthcareResearch and Experimental DevelopmentBelow IPO PriceHigh-Performing StocksHepatitis ConceptMargin Trading and Securities LendingHigh-Dividend StocksHigh-Dividend Yield StocksChiNext 300 IndexChiNext Small Cap

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 12163.67
  • Circulating A-Shares(W): 11958.06
  • Earnings Per Share(RMB): 0.9058
  • Net Assets Per Share(RMB): 43.3830
  • Operating Revenue(W RMB): 51144.50
  • Total Profit(W RMB): 12447.30
  • Net Profit Attributable to Parent(W RMB): 11017.95
  • Net Profit Growth Rate(%): 10.94
  • Weighted Return on Equity(%): 1.9000
  • Operating Cash Flow Per Share(RMB): 0.6820
  • Undistributed Profit Per Share(RMB): 6.0642
  • Capital Reserve Per Share(RMB): 35.7924

2. Main Business

The main business covers:

  • Research, development, production, sales and technical services of biological reagents.

3. Company Basic Information

  • Company Name: Beijing Sino Biological Technology Co., Ltd.
  • Listing Date: 2021-08-16
  • Industry: Research and Experimental Development
  • Address: Room 306, Building 9, No. 18 Kechuang 10th Street, Beijing Economic-Technological Development Area, Beijing, China.
  • Website: www.sinobiological.com
  • Company Profile: The issuer was established by the overall change of Sino Biological Limited to a joint stock company. On March 25, 2020, the board of directors of Sino Biological Limited agreed to change Sino Biological Limited into a joint stock company. On March 26, 2020, Sino Biological Technology held its inaugural meeting, and all shareholders signed the "Sponsor Agreement". According to the "Evaluation Report" issued by Northern Asia (Northern Asia Ping Bao Zi [2020] No. 01-081), the assessed net assets of Sino Biological Limited as of November 30, 2019 were 188.4668 million yuan. According to the "Audit Report" issued by Grant Thornton (Grant Thornton Zhuan Zi (2020) No. 110ZA2971), the audited net assets of Sino Biological Limited as of November 30, 2019, amounting to 177.5262 million yuan, were converted into the share capital of Sino Biological Technology at a ratio of 3.4809:1, totaling 51.00 million shares, with a par value of RMB 1 per share. The portion of net assets exceeding the share capital was included in capital reserve. On March 26, 2020, Grant Thornton issued the "Capital Verification Report" (Grant Thornton Yan Zi (2020) No. 110ZC0060), confirming that the company had received the net assets subscribed by all contributors, and the above net assets were converted into a total share capital of 51.00 million shares. On March 27, 2020, Sino Biological Technology obtained the business license reissued by the Beijing Administration for Industry and Commerce Economic-Technological Development Area Branch.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Lhasa Ailike Investment Consulting Co., Ltd. General Legal Person 6514.01 54.47
2 Xuzhou Yiqiao An Zhi Yuan Enterprise Management Consulting Partnership (Limited Partnership) General Legal Person 390.16 3.26
3 Tianjin Yiqiao An Heng Enterprise Management Consulting Partnership (Limited Partnership) General Legal Person 136.60 1.14
4 Hong Kong Securities Clearing Company Ltd. Northbound Capital 91.96 0.77
5 Xuzhou Yiqiao An Zhi Tai Enterprise Management Consulting Partnership (Limited Partnership) General Legal Person 86.81 0.73
6 Xuzhou Yiqiao An Zhi Cheng Enterprise Management Consulting Partnership (Limited Partnership) General Legal Person 85.02 0.71
7 Xuzhou Yiqiao An Zhi He Enterprise Management Consulting Partnership (Limited Partnership) General Legal Person 84.70 0.71
8 Xuzhou Yiqiao An Zhi Ping Enterprise Management Consulting Partnership (Limited Partnership) General Legal Person 57.00 0.48
9 Huahong Qiangzhen (Xiamen) Enterprise Management Consulting Partnership (Limited Partnership) General Legal Person 51.01 0.43
10 China Merchants Guozheng Biomedicine Index Securities Investment Fund (LOF) Class A Fund 5.13 0.04

5. Concept Sectors

  • Immunotherapy
  • Smart Healthcare
  • Artificial Intelligence
  • CXO Concept
  • Hepatitis Concept
  • Synthetic Biology
  • AI Healthcare
  • Margin Trading & Securities Lending
  • High-Performance Stock
  • High-Dividend Stock
  • Below IPO Price
  • High-Dividend-Payout Stock
  • ChiNext 300
  • ChiNext Small Cap

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information